6 Dimensions Capital

6 Dimensions Capital is a venture capital firm specializing in innovative startups, early stage, and growth capital investments. The firm seeks to invest in any sector and stage. It typically invests in the healthcare and life sciences sector with a focus on medical devices, digital health, diagnostics, and pharmaceuticals. The firm seeks to invest in companies based in China and the United States. 6 Dimensions Capital was founded in 2011 and is based in Cambridge, Massachusetts with an additional office in Shanghai, China.
LC

Leon Chen

CEO and Founding Partner

EH

Erdong Hua

Partner

Zhujie Li

Managing Partner

WL

Wei Li

Managing Partner

QX

Qin Xie

Partner

RZ

Rebecca Zhu

Partner

CZ

Ching Zhu

Managing Partner

38 past transactions

Curon Biopharma

Series A in 2018
Curon Biopharma is a developer of drugs intended designed for immuno-oncology therapies. The company's drugs consist of multiple class-leading cancer immunotherapeutic agents in the world that could address the shortcomings of current cancer treatment paradigm, enabling a physician to provide advanced cancer immunotherapies to their patients.

HiberCell

Series A in 2019
They are proud to be supported by some of the world’s most visionary investors in biotechnology. Their investors share our commitment and vision to change the way they think about and treat metastatic, relapsed cancer.

AnchorDx

Series B in 2017
Guangzhou Baseline Medical is committed to building a world-class clinical application of high-throughput sequencing and R & D platform to become the leading global provider of precision medical solutions. The company's core team has more than 20 years of senior industry experience, involved in cancer genomics, genetics and bioinformatics and other fields. Based on its core technical advantages, the Company aims at precision medicine, establishes a cooperative relationship with middle and downstream enterprises in the industry, and forms a complete industrial chain from academic research to clinical product transformation. It has also established close cooperation with many large-scale third-party inspection agencies including Illumina, Well-known domestic and foreign hospitals and research institutes to establish cooperative relations, the development of a series of independent intellectual property rights and international competitiveness of clinical testing products for patients, doctors and medical institutions to provide accurate, convenient and comprehensive services.

Kira Pharmaceuticals

Venture Round in 2020
Kira Pharmaceuticals is a developer and researcher of antibody drugs and immunoantibody therapy. The company is mainly engaged in the research, development and production of antibody medicine to treat various diseases, providing healthcare patients with better treatments and therapy.

Halda Therapeutics

Series A in 2019
Halda Therapeutics is a research-stage drug discovery company, seeking to create the next generation of precision medicine based on a novel therapeutic modality which may be a platform for a number of disease states.

TScan Therapeutics, Inc.

Series B in 2020
TScan Therapeutics is an experienced group of scientists, development specialists, and other leaders driving a cutting edge platform. TScan Therapeutics is an owner and operator of a biotechnology company intended to develop immunotherapy treatments for cancer. The company identifies T-cell targets in a genome-wide high-throughput manner, expanding the treatment of immuno-oncology to patients who have few therapeutic options. TScan Therapeutics is harnessing novel T cell systems to extend the promise of immunotherapy. The company is dedicated to changing lives by discovering new cancer targets and developing safe and effective T-cell therapies for patients.

Viela Bio

Series A in 2018
Viela Bio is a clinical-stage biotechnology company engaged in developing and commercializing transformative treatments for severe inflammation and autoimmune diseases. Its product inebilizumab, is a humanized monoclonal antibody, designed to target CD19, a molecule expressed on the surface of a broad range of immune system B cells.
Gracell Biotechnologies is a developer of cancer immune therapy designed to treat cancer. The company's therapy offers cellular therapeutics for the patients suffered from hematological malignancy, solid tumor or degenerative disease, enabling healthcare providers to cure their patients and improve their lives.

HiberCell

Series A in 2019
They are proud to be supported by some of the world’s most visionary investors in biotechnology. Their investors share our commitment and vision to change the way they think about and treat metastatic, relapsed cancer.

Exo Therapeutics

Series A in 2020
Exo Therapeutics, Inc. is a molecule drug discovery and development company to address intractable pharmaceutical targets. The company develops a pipeline of drug candidates that bind exosites, distal, and unique binding pockets that reprogram enzyme activity for therapeutic effect in oncology, inflammation. Exo Therapeutics, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

MitrAssist

Venture Round in 2020
MitrAssist introduces a minimally invasive approach to MR treatment. Its mitral valve implant works in unison with the natural mitral valve without harming its functionality. MitrAssist has developed a new approach to treating MR that is neither repair nor replacement. Instead, its proprietary valve implant is placed on top of the natural valve to work in unison with it and to enhance valve functionality. MitrAssist’s “valve-in-valve” approach overcomes the various challenges of MR and offers an improved treatment solution for all MR patients. It has significant advantages over minimally invasive solutions – both existing and in development.

Jiecheng Medical

Series A in 2013
"Suzhou Jiecheng Medical Technology Co., Ltd." is a high-tech medical technology company with completely independent intellectual property rights and its patented technology is in a leading position in the world. The company was established in September 2009. The R&D team consists of Cardiologist Zhang Ji and several domestic and foreign R&D experts. The company's leading project is the development and production of the innovative "J-Valve Precision Positioning Heart Valve Implant System" technology. "J-Valve Precise Positioning Heart Valve Implant System" is a minimally invasive surgical technique that eliminates the need to open a chest and eliminates extracorporeal blood circulation. It can significantly reduce patient's surgical trauma, shorten postoperative recovery time, reduce patient's pain, and reduce The requirements of the patient's physical condition, thereby expanding the range of application of the disease, improving the efficacy of treatment, reducing the cost of surgery, so that the majority of patients need to replace the heart valve can be treated. Other similar products can only be implanted into the heart through the use of imaging technology. The J-Valve system can completely rely on its own positioning device to assist doctors in performing valve replacement surgery, thereby reducing the risk of surgery, easier to operate and master, and simplifying the heart valve Replacement process. The above advantages will help reduce the overall cost of the country's health care system, promote the reform of the health care system, reduce medical costs, and save social medical resources. At the same time, drastic changes in the long-term dependence on

Biokangtai

Post in 2018
Shenzhen Kangtai Biological Products Co., Ltd. is a listed company integrating research, development, production and sales of biological products.the company has R&D centers and industrial bases in Shenzhen and Beijing. It is one of the major hepatitis B vaccine manufacturers in China.The company's main business is the development, production and sales of human vaccines. The product categories cover Class I and Class II vaccines. The main products are recombinant hepatitis B vaccine (Saccharomyces cerevisiae), Haemophilus influenzae type b conjugate vaccine, and measles and rubella. Live attenuated vaccine, cell-free white-breaking Haemophilus influenzae type b combined vaccine, 23- valent pneumococcal polysaccharide vaccine and other products.

Exo Therapeutics

Series B in 2021
Exo Therapeutics, Inc. is a molecule drug discovery and development company to address intractable pharmaceutical targets. The company develops a pipeline of drug candidates that bind exosites, distal, and unique binding pockets that reprogram enzyme activity for therapeutic effect in oncology, inflammation. Exo Therapeutics, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Ultivue

Series C in 2019
Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing. Ultivue produces reagents that enable researchers to obtain microscopic images at an unprecedented resolution that helps to understand of biology and medicine. Ultivue's products are designed for fluorescent microscopy-based research and will eventually be valuable for clinical diagnostic use. It was founded in 2015 and headquartered in Cambridge, Massachusetts.

Yiyao

Series E in 2018
Yiyao is also knwon as 111.com.cn. Yiyao is an online drug superstore where patients can buy over-the-counter medications, traditional Chinese remedies, and a variety of other health products including everything from sex toys to diet pills. 111.com.cn operates as an online portal for selling pharmaceutical products.

Dewpoint Therapeutics

Series A in 2019
Dewpoint Therapeutics, Inc., a biotech company, engages in research of biomolecular condensates and cellular function to develop treatments for diseases like cancer, neurodegenerative disorders, immunology, cardiovascular, women’s health, and virology. The company was incorporated in 2018 and is based in Boston, Massachusetts.

TScan Therapeutics, Inc.

Series C in 2021
TScan Therapeutics is an experienced group of scientists, development specialists, and other leaders driving a cutting edge platform. TScan Therapeutics is an owner and operator of a biotechnology company intended to develop immunotherapy treatments for cancer. The company identifies T-cell targets in a genome-wide high-throughput manner, expanding the treatment of immuno-oncology to patients who have few therapeutic options. TScan Therapeutics is harnessing novel T cell systems to extend the promise of immunotherapy. The company is dedicated to changing lives by discovering new cancer targets and developing safe and effective T-cell therapies for patients.

Fog Pharmaceuticals, Inc.

Series B in 2018
FogPharma derives financial support from a unique syndicate of extraordinary private and institutional investors. FogPharma’s network of friends includes our founders, employees, investors, advisors, collaborators, and cancer patients; all working together to pioneer a unique approach toward conquering cancer. FogPharma is laser-focused and unstoppable in its mission to deliver the new class of medicines to patients and their families to bring them years to life and life to years.

NeuSpera Medical

Series B in 2019
NeuSpera Medical Inc. develops and manufactures ultra-miniaturized implantable devices for neuromodulation therapy. Its Neuspera Mid-Field Powering technology uses the body as a natural waveguide to direct energy. NeuSpera Medical Inc. was formerly known as Vivonda Medical Incorporated. The company was incorporated in 2013 and is based in San Jose, California.

NeuSpera Medical

Series B in 2018
NeuSpera Medical Inc. develops and manufactures ultra-miniaturized implantable devices for neuromodulation therapy. Its Neuspera Mid-Field Powering technology uses the body as a natural waveguide to direct energy. NeuSpera Medical Inc. was formerly known as Vivonda Medical Incorporated. The company was incorporated in 2013 and is based in San Jose, California.

Kymera Therapeutics

Series B in 2018
Kymera Therapeutics, Inc., a biopharmaceutical company, focuses on discovering and developing novel small molecule therapeutics that selectively degrade disease-causing proteins by harnessing the body’s own natural protein degradation system. It engages in developing IRAK4 program for the treatment of immunology-inflammation diseases, including hidradenitis suppurativa, atopic dermatitis, and rheumatoid arthritis; IRAKIMiD program to treat MYD88-mutated diffuse large B cell lymphoma; and STAT3 program for the treatment of hematologic malignancies and solid tumors, as well as autoimmune diseases. The company was founded in 2015 and is headquartered in Watertown, Massachusetts.
Fulcrum Therapeutics is a biotechnology company developing new medicines to deliver a new future to patients. The company develops a proprietary product engine that employs to identify and validate cellular drug targets that can modulate gene expression. Its product candidate, losmapimod, is a small molecule that was developed for the treatment of FSHD, a muscle-wasting disorder that leads to physical impairments and disability. It is focused on improving the lives of patients with genetically defined diseases in areas of high unmet medical need, with an initial focus on rare diseases.

Lyvgen

Series B in 2018
Lyvgen Biopharma Co. Ltd. researches, develops, and produces immuno-oncology drugs candidates. The company offers antibodies, including PD-1 antibody SSI-361, which is a set of proprietary co-stimulation agonist biotherapeutics that helps to activate specific receptors in the tumor microenvironment while reducing immune-mediated adverse effects in healthy tissue. The company was founded in 2016 and is based in Shanghai, China.

Iteos Therapeutics S.A.

Series B in 2018
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for cancer patients. Its product pipeline includes EOS-850, a small molecule antagonist of the adenosine A2a receptor that is an open-label Phase 1/2a clinical trial in adult patients; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2a clinical trial. The company was founded in 2011 and is headquartered in Cambridge, Massachusetts.

Engine Biosciences

Seed Round in 2018
Engine Biosciences Pte. Ltd. develops a validated platform for drug discovering, developing combination therapeutics, and cellular reprogramming. The company's artificial intelligence and genetic perturbation platform allows researchers and drug developers to uncover the gene interactions and biological networks. It provides test therapies that specifically target genetic interactions, and make analyses and predictions for precision medicine applications. The platform provides drug discovery, such as target discovery, drug repositioning, repurposing, pathway, and massive online analysis (MoA) analysis. It caters to the American fortune 500 companies and research institutions. The company was founded in 2014 and is based in Singapore.

Brii Biosciences

Venture Round in 2018
Brii Biosciences is a developer of bio-pharmaceutical medicines intended to provide medical solutions to Chinese patients to fulfill their health and treatment needs. The company's medicines focuses on infectious disease drug development and commercialization in China and leverage technology and data to drive improvements to the Chinese healthcare system and outcomes for patients, enabling patients to get access to better treatments and cures for life-threatening diseases.

GKHT Medical Technology

Series C in 2019
Guoke Hengtai (Beijing) Medical Technology Co., Ltd. was established in February 2013 and is affiliated to Oriental Science and Technology Holding Group Co., Ltd. (hereinafter referred to as “Oriental Instrument”), a subsidiary of the State-owned Assets Supervision and Administration Commission of the Chinese Academy of Sciences. It is headquartered in Yizhuang Economic and Technological Development Zone, Beijing. . Since the establishment of Guoke Hengtai for 4 years, the company has experienced two rounds of investment in A and B, and its performance has continued to grow at a high speed, with a compound annual growth rate of over 50%. In 2017, the company officially launched the IPO listing journey.

Helian Health

Series A in 2017
Helian Health provides wifi services at hospitals and online healthcare platforms serving patients and doctors. It develops applications, including Xiaohe Yizhu, which allows healthcare professionals to store health records in the cloud, share case studies and take medical images; and Hejiankang, which allows companies to provide personalized health recommendations for their employees. The company was founded in 2014 and is based in Hangzhou, China.

Ultivue

Series B in 2018
Ultivue is a biotechnology company that specializes in tissue imaging, diagnostics, and multiplexing. Ultivue produces reagents that enable researchers to obtain microscopic images at an unprecedented resolution that helps to understand of biology and medicine. Ultivue's products are designed for fluorescent microscopy-based research and will eventually be valuable for clinical diagnostic use. It was founded in 2015 and headquartered in Cambridge, Massachusetts.
Haoxinqing is an online medical service platform focusing on the fields of mental psychology and chronic disease management.

GloriousMed Technology

Series A in 2018
GloriousMed Technology is a Healthcare company.

Medeor Therapeutics

Series B in 2017
Medeor Therapeutics is a developer of cellular immunotherapies designed to improve outcomes in organ transplant recipients. The company's cellular immunotherapies consist of approaches to organ transplant immune tolerance and immuno-oncology, enabling healthcare providers to preserve or improve transplant kidney function and prevent graft rejection better than currently available immunosuppression (anti-rejection) drugs.
Forerunner Medical (Shanghai) Co., Ltd. develops and manufactures medical devices for minimally invasive treatment. It primarily develops and produces low-temperature plasma radiofrequency generators and electrodes for sport medicine, disk demo-pression, and ENT treatment applications. Its products include plasma radiofrequency systems; and electrodes for joint, spine, cervical, lumbar, transforaminal endoscopic operation, and ENT treatment applications. The company was founded in 2009 and is based in Shanghai, China.

Grail

Series C in 2018
GRAIL, Inc., a healthcare company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer test to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer. It is also developing minimal residual disease and other post-diagnostic tests. The company was founded in 2015 and is headquartered in Menlo Park, California.